PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsImiquimod
Aldara, Zartra(imiquimod)
Aldara, Imiquimod, Zyclara (imiquimod) is a small molecule pharmaceutical. Imiquimod was first approved as Aldara on 1997-02-27. It is used to treat actinic keratosis, basal cell carcinoma, and condylomata acuminata in the USA. It has been approved in Europe to treat actinic keratosis, basal cell neoplasms, condylomata acuminata, and keratosis.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
neoplasmsD009369
urogenital diseasesD000091642
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Imiquimod, Zyclara (discontinued: Aldara, Imiquimod)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Imiquimod
Tradename
Company
Number
Date
Products
ZYCLARABausch Health CompaniesN-022483 RX2010-03-25
2 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
imiquimodANDA2025-08-11
imiquimod 5% / levocetirizine dihydrochloride 1% / niacinamide 2%unapproved drug other2019-04-23
imiquimod 5% / levocetirizine dihydrochloride 1% / tretinoin 0.05%unapproved drug other2019-04-23
imiquimod 5% / niacinamide 4%unapproved drug other2019-05-06
imiquimod 5% / salicylic acid 30% / tretinoin 0.1%unapproved drug other2019-05-06
imiquimod 5% / tretinoin 0.025%unapproved drug other2019-05-06
zyclaraNew Drug Application2025-05-23
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Imiquimod, Zyclara, Bausch
109186352030-04-30U-172, U-1455
112027522030-04-30U-172, U-1455
82222702029-12-11U-68
82368162029-12-11U-68
82991092029-12-11U-68
102386442029-12-11U-68
113181302029-12-11U-68
85981962029-08-18U-172, U-1455
102386452029-08-18U-172, U-1455
Imiquimod, Aldara, Bausch
76961592024-04-01DPU-1047, U-1048
ATC Codes
D: Dermatologicals
D06: Antibiotics and chemotherapeutics for dermatological use
D06B: Chemotherapeutics for topical use
D06BB: Antivirals, topical
D06BB10: Imiquimod
HCPCS
No data
Clinical
Clinical Trials
192 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Actinic keratosisD055623L57.026913737
KeratosisD00764226913737
CarcinomaD002277C80.05474322
Basal cell carcinomaD0022801174316
Basal cell neoplasmsD0182951164315
Carcinoma in situD002278D09.93561215
WartsD014860B07233210
Squamous cell carcinomaD002294311117
Squamous intraepithelial lesions of the cervixD065310122117
Condylomata acuminataD003218EFO_0007147A63.01315
Show 12 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C80565417
Uterine cervical dysplasiaD002578EFO_1000910N87345414
MelanomaD00854584112
Cervical intraepithelial neoplasiaD06235412
RecurrenceD01200844219
Human influenzaD007251EFO_0007328J11.111226
Skin neoplasmsD012878EFO_0004198C442114
Hepatitis bD006509323
Papillomavirus infectionsD03036133
InfectionsD007239EFO_0000544123
Show 18 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
GliomaD005910EFO_000052010110
GlioblastomaD005909EFO_0000515515
Breast neoplasmsD001943EFO_0003869C50335
Urinary bladder neoplasmsD001749C67314
Uterine cervical neoplasmsD002583134
Colorectal neoplasmsD015179313
Ovarian neoplasmsD010051EFO_0003893C561113
Fallopian tube neoplasmsD0051851113
Prostatic neoplasmsD011471C61223
Non-small-cell lung carcinomaD0022891113
Show 22 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients44
Renal cell carcinomaD002292EFO_000037622
Stomach neoplasmsD013274EFO_0003897C1622
T-cell lymphomaD016399112
T-cell lymphoma cutaneousD016410C84.A112
AdenocarcinomaD00023022
Skin agingD015595EFO_0005422112
MycosesD009181B35-B49112
Mycosis fungoidesD009182C84.0112
Brain neoplasmsD001932EFO_0003833C7122
Show 22 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Peritoneal neoplasmsD01053411
Chronic diseaseD00290811
PruritusD011537L2911
LymphomaD008223C85.911
T-cell lymphoma peripheralD01641111
Skin diseasesD012871L00-L9911
PsoriasisD011565EFO_0000676L4011
FeverD005334R50.911
HyperthermiaD00008446211
SinusitisD012852EFO_0007486J3211
Show 5 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameImiquimod
INNimiquimod
Description
Imiquimod is an imidazoquinoline fused [4,5-c] carrying isobutyl and amino substituents at N-1 and C-4 respectively. A prescription medication, it acts as an immune response modifier and is used to treat genital warts, superficial basal cell carcinoma, and actinic keratosis. It has a role as an antineoplastic agent and an interferon inducer.
Classification
Small molecule
Drug classimmunomodulators
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(C)Cn1cnc2c(N)nc3ccccc3c21
Identifiers
PDB
CAS-ID99011-02-6
RxCUI
ChEMBL IDCHEMBL1282
ChEBI ID36704
PubChem CID57469
DrugBankDB00724
UNII IDP1QW714R7M (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
£
No data
Estimated US medical usage
Imiquimod
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 17,131 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
2,462 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use